A 2026 lab-based emissions study from IITGN and UIUC, published in the Journal of Hazardous Materials, tested just six commercial cigarette varieties—two tobacco brands and four herbal blends—using an automated smoking rig to measure sub-500 nm particles and oxidative potential (OP). This was an experimental characterization study, not an RCT or observational human trial, with a small sample of Indian-market products and no reported conflicts of interest. Results showed herbal smoke produced ~20% higher fine-particle concentrations and elevated OP, with tendu-leaf-wrapped variants 49% higher than paper-wrapped ones, driven by leaf combustion chemistry rather than nicotine. The original MedicalXpress coverage accurately summarized these metrics but missed the direct parallel to bidis, whose tendu wrappers have long been linked in prior research to higher toxin yields (see: Tobacco Control 2019 meta-analysis of bidi emissions). It also overlooked how India's COTPA framework creates a documented loophole: tobacco-free products escape warning-label mandates, a pattern seen in other jurisdictions where 'natural' claims similarly delay regulation. Consumers drawn to basil- or clove-filled options for cough relief or sleep benefits face the same cardiovascular and respiratory pathways as tobacco users, since OP drives inflammation independent of nicotine. Public-health messaging must therefore target emission chemistry, not just ingredient lists, to counter the marketing that fuels these purchases.